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Abstract
Purpose A novel transdermal formulation of granisetron
(the granisetron transdermal delivery system (GTDS)) has
been developed to deliver granisetron continuously over
7 days. This double-blind, phase III, non-inferiority study
compared the efficacy and tolerability of the GTDS to daily
oral granisetron for the control of chemotherapy-induced
nausea and vomiting (CINV).
Patients and methods Six hundred forty-one patients were
randomized to oral (2 mg/day, 3–5 days) or transdermal
granisetron (one GTDS patch, 7 days), before receiving
multi-day chemotherapy. The primary endpoint was com-
plete control of CINV (no vomiting/retching, no more than
mild nausea, no rescue medication) from chemotherapy
initiation until 24 h after final administration. The prespe-
cified non-inferiority margin was 15%.
Results Five hundred eighty-two patients were included in
the per protocol analysis. The GTDS displayed non-
inferiority to oral granisetron: complete control was
achieved by 60% of patients in the GTDS group, and
65% in the oral granisetron group (treatment difference,
−5%; 95% confidence interval, −13–3). Both treatments
were well tolerated, the most common adverse event being
constipation.
Conclusions The GTDS provides effective, well-tolerated
control of CINV associated with moderately or highly
emetogenic multi-day chemotherapy. It offers a convenient
alternative route for delivering granisetron for up to 7 days
that is as effective as oral granisetron.
Keywords Cancer.Chemotherapy-induced nausea and
vomiting (CINV).Granisetron.Multi-day.Transdermal
Introduction
Multi-day chemotherapy is associated with a substantial
risk of chemotherapy-induced nausea and vomiting (CINV)
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DOI 10.1007/s00520-010-0990-y[1], yet remains the mainstay of treatment strategies for
many cancers [2, 3]. Prophylaxis of CINV associated with
multi-day chemotherapy is, therefore, a key clinical goal
and, although relatively under-represented in the literature
[4, 5], an important area of research.
The management of CINV in patients receiving multi-
day chemotherapy presents additional challenges, compared
to single-day chemotherapy. The pathophysiology of CINV
in this setting is complicated by the overlap of acute and
delayed nausea and vomiting, making meaningful distinc-
tion between these two parameters difficult and requiring
use of overall protection from nausea and vomiting as a
primary endpoint [2]. Repeated administration of medica-
tions over several days can give rise to peaks and troughs in
plasma drug levels [6, 7]. In addition, such treatment may
require a high tablet burden and complex dosing regimen,
with potential detrimental effects on treatment adherence
[8]. Delivery of antiemetic therapy from a transdermal
system may help to reduce these obstacles to CINV control.
Current guidelines for the management of multi-day
CINV recommend 5-hydroxytryptamine subtype 3 (5-HT3)
receptor antagonists (RAs) as a basis for treatment, to
which corticosteroids, with or without a neurokinin-1
(NK-1) RA, may be added [5, 9, 10]. The commonly used
5-HT3 RA granisetron is currently available for oral and
intravenous administration. A new formulation, the grani-
setron transdermal delivery system (GTDS; Sancuso®,
ProStrakan Pharmaceuticals), has been developed to pro-
vide extended release of granisetron over 7 days. The
GTDS patch is an 8×6-cm clear plastic-backed patch with
an adhesive layer containing 34.3 mg of granisetron.
Pharmacokinetic evaluation of the GTDS has indicated that
it provides continuous delivery of granisetron over 7 days,
providing exposure similar to an oral dose of 2 mg per day
[11]. Transdermal delivery offers a convenient non-invasive
option for sustained antiemetic administration and could
enable continuous antiemetic prophylaxis throughout a
multi-day chemotherapy regimen.
This study compares the efficacy and tolerability of the
GTDS with those of oral granisetron for controlling CINV
in patients receiving moderately emetogenic chemotherapy
(MEC) or highly emetogenic chemotherapy (HEC) regi-
mens for 3–5 days.
Methods
Patients
Adult cancer patients (≥15, 16, or 18 years, dependent on
local regulations) assigned to receive the first cycle of a
new multi-day MEC or HEC regimen were eligible for
enrolment in the study. An emetogenicity classification for
multi-day chemotherapy was devised based on the single-
agent Hesketh level for the most emetogenic agent,
modified when additional emetogenic agents were included
in the regimen (online resource, section 1)[ 12]. MEC and
HEC regimens were defined as those with maximum
emetogenicity levels of 3–4 and >4, respectively, for a
3–5-day period.
Inclusion criteria included an Eastern Cooperative
Oncology Group (ECOG) status ≤2 and a life expectancy
of ≥3 months. The primary exclusion criteria included:
hypersensitivity to adhesive plasters; contraindications to
5-HT3 RAs; participation in any previous clinical study
with the GTDS; any cause for nausea and vomiting other
than CINV, including radiotherapy within 1 week of entry;
any retching, nausea, or uncontrolled vomiting within 72 h
before chemotherapy initiation; clinically relevant abnormal
ECG parameters; and/or baseline QTc prolongation.
Study design
This was a randomized, active control, double-blind, parallel-
group, phase III study, conducted at 60 centers in Europe,
India, Mexico, and the USA. The primary objective was to
demonstrate non-inferiority of GTDS efficacy compared
to oral granisetron, in patients receiving MEC or HEC.
Secondary objectives included assessment of the safety,
tolerability, and adhesive properties of the GTDS.
Following a 7-day screening period, patients were
randomized in a 1:1 ratio using a telephone-based random-
ization system to receive either a GTDS patch and placebo
capsules or a placebo patch and active capsules (2 mg
granisetron). Active and placebo medications were identical
in appearance to ensure blinding. Patients were allocated to
treatment in a random permuted block design, 1–2 days
before initiation of chemotherapy. Stratification was based
on factors known to affect CINV, including gender, planned
chemotherapy regimen and duration, and chemotherapy
naivety. Stratification of chemotherapy regimens was based
on the inclusion or exclusion of cisplatin in the regimen;
non-cisplatin regimens were further divided based on the
planned inclusion of corticosteroids as part of the antie-
metic regimen. The use of corticosteroids with cisplatin
regimens was not included in the stratification, as it was
anticipated that the vast majority of patients receiving
cisplatin would also receive corticosteroids as part of the
regimen. The use of corticosteroids in this group was
recorded for confirmation.
Due to the gradual dermal penetration of granisetron
from the transdermal system, patches were applied to the
upper arm 24–48 h before the start of chemotherapy, by the
investigator or the patient, and left in place for 7 days.
Capsules were administered 1 h before each day’sa d m i n i s -
tration of chemotherapy (online resource, section 1). Patches
1610 Support Care Cancer (2011) 19:1609–1617were left in place for a full 7 days in all patients in order to
increase the amount of safety data collected. Corticosteroids
were permitted at the discretion of the investigator, as
prophylaxis, and started before chemotherapy. The use of
other concomitant therapies was permitted, excluding con-
comitant radiotherapy; medication to control the symptoms
of a brain tumor, brain metastasis, or seizure disorder; SSRI
antidepressants (unless a stable dose for the duration of the
study); drugs known to increase the QTc interval; any other
investigational drug; and any NK-1 RA, dopamine RA,
or 5-HT3 RA.
Prescription of rescue medication not known to cause
QTc prolongation was permitted at the discretion of the
investigator, in accordance with the site’s standard of care.
Increased use of corticosteroids above that planned in the
chemotherapy regimen was recorded as rescue medication.
All patients provided written informed consent before
enrolment into the study. The study protocol was approved
by the Ethics Committee/Institutional Review Board at each
participating center and was conducted in accordance with
the Declaration of Helsinki.
Efficacy parameters
The primary efficacy endpoint was the percentage of patients
achieving complete control of CINV (CC; no vomiting and/or
retching, no more than mild nausea, and no use of rescue
medication) from the first administration until 24 h after the
last administration of chemotherapy (the primary endpoint
evaluationperiod(PEEP);onlineresource,Figure S1). Nausea
and vomiting were assessed using patient diaries, completed
on a daily basis. Patients reported the presence and severity of
nausea on a four-point scale (none, mild, moderate, severe)
and the presence and severity of vomiting on a five-point
scale (none, mild, moderate, severe, very severe).
Exploratory analyses of the primary endpoint included
analysis in predefined subgroups based on randomization
stratificationvariables.Secondaryefficacyendpointsincluded
the timetofailure ofCC; the percentageofpatientsfailing CC
due to nausea, vomiting, or receipt of rescue medication; the
percentage of patients achieving complete response (CR; no
vomiting and/or retching, no rescue medication) or total
control (TC; no vomiting and/or retching, no nausea, no
rescue medication) during the PEEP (overall and by day);
patients’ global satisfaction with antiemetic therapy (assessed
using a 10-cm visual analog scale (VAS) at the time of patch
removal); and the percentage adhesion of the patch over the
application period.
Study visits and evaluations
Patients were assessed for eligibility 4–12 days before
initiation of chemotherapy. Assessments of efficacy, toler-
ability, and safety variables were performed throughout
the study period, including a 14-day follow-up after patch
removal (online resource, Figure S1). Emesis control, rescue
medication, and patch adhesion were recorded using patient
diary cards, distributed at visit 1.
Statistical analysis
The primary efficacy endpoint was assessed using a non-
inferiority model, with a non-inferiority margin (Δ)o f
15%. This non-inferiority margin was based on previous
non-inferiority studies of 5-HT3 RA antiemetics in CINV
[13, 14], and is consistent with FDA and EU reviews of
alternative 5-HT3 RAs [15, 16], to which granisetron has
demonstrated equivalence [17]. Assuming 50% CC with
oral granisetron and a difference between treatment groups
of ≤15% (the non-inferiority margin), 576 patients were
required to ensure 90% power. Using a predicted drop-out
rate of 9%, randomization of 630 patients was planned.
Non-inferiority of the GTDS compared to oral granisetron
wasassessedbyconstructingapointestimateofthedifference
in emetic control between treatments. Non-inferiority was
accepted if the lower limit of the two-sided 95% confidence
interval (CI) of this point estimate was greater than −Δ.
Differences between treatments, and corresponding CIs, were
evaluated using a logistic regression model, adjusting for
study treatment and randomization stratification variables.
Inferiority limits were not prespecified for exploratory
analyses. Statistical significance of differences in secondary
endpoints was calculated using Cox’s proportional hazard
model (time to events), logistic regression (CR and TC),
and analysis of covariance (patients’ global satisfaction).
Statistical analyses were performed in the safety set
(SS; all patients who received at least one dose of study
treatment), the full analysis set (FAS; all SS patients who
had ≥1 efficacy assessment), and the per protocol set (PPS;
all FAS patients who had no protocol violations that
directly impinged on or affected the primary endpoint,
defined before unblinding). As this was a non-inferiority
study, the primary efficacy analysis was performed in the
PPS. This is in line with guidelines from the International
Conference on Harmonisation, and aims to avoid the
tendency towards equivalence associated with intent-to-
treat analyses [18]. The results were validated using
additional analyses in the FAS [18].
Results
Patient characteristics
The study was carried out between January and October
2006. Of 715 patients assessed for eligibility, 641 were
Support Care Cancer (2011) 19:1609–1617 1611randomized to receive the GTDS (n=318) or oral granisetron
(n=323). Of these patients, 637 were in the SS, 621 were in the
FAS, and 582 were in the PPS; reasons for withdrawal were
similar between the two treatment groups (Fig. 1). Baseline
demographic and medical characteristics, including stratifica-
tion variables, were comparable between the two treatment
groups (Table 1). Baseline characteristics in the SS and PPS
were similar to the FAS (data not shown). Prophylactic use of
corticosteroids was well balanced between the two arms
(GTDS group, 61.0%; placebo group, 61.7%). In the FAS,
71% of GTDS patients and 72% of oral granisetron patients
received regimens containing one or more days of cisplatin.
Assessed for
eligibility
(n = 715)
Randomized
(n = 641)
GTDS
(n = 318)
Oral
granisetron
(n = 323)
Safety set
(n = 316)
Safety set
(n = 321)
Full analysis
set (n = 308)
Full analysis
set (n = 313)
Completed study
(n = 296)
￿ Per protocol
set (n = 284)
Withdrawn:
received no
medication (n = 2)
Withdrawn:
received no
medication (n = 2)
Excluded (n = 74)
￿ Screening failure (n = 72)
 – Withdrawal of consent = 25
 – Other protocol violation = 23
 – Violation of inclusion/exclusion criteria = 16
 – Adverse event(s) = 5
 – Study terminated = 3
￿ Randomization failure (n = 2)
 – Withdrawal of consent = 1
 – Violation of inclusion/exclusion criteria = 1
Withdrawn (n = 20)
￿ Patch applied, no capsule taken (n = 7)
 – Insufficient patch adhesion = 2
 – Adverse event(s) = 2
 – Non-compliance = 1
 – Violation of inclusion/exclusion criteria = 1
 – Death = 1
￿ Patch applied, ≥1 capsule taken (n = 13)
 – Death = 5
 – Adverse event(s) = 4
 – Lack of efficacy of trial treatment = 2
 – Withdrawal of consent = 1
 – Other = 1
Withdrawn (n = 17)
￿ Patch applied, no capsule taken (n = 3)
 – Insufficient patch adhesion = 1
 – Lack of efficacy of trial treatment = 1
 – Withdrawal of consent = 1
￿ Patch applied, ≥1 capsule taken (n = 14)
 – Adverse event(s) = 5
 – Death = 5
 – Violation of inclusion/exclusion criteria = 1
 – Non-compliance = 1
 – Withdrawal of consent = 1
 – Other = 1
Completed study
(n = 304)
￿ Per protocol
set (n = 298)
Fig. 1 Flow of participants through the study SS, all patients who
received ≥1 dose of study treatment. FAS, all SS patients who had ≥1
efficacy assessment after the start of chemotherapy. PPS, all FAS
patients without protocol violations that directly impinged on or
affected the primary endpoint. Protocol violations leading to exclusion
from the PPS included changes in the planned chemotherapy regimen,
receipt of banned concomitant medications, >50% patch detachment
and incorrect study drug administration
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The study met its predefined primary endpoint. The lower
limit of the 95% CI of the difference between the treatments
was greater than −15%, indicating that the GTDS was non-
inferior relative to oral granisetron. The number of patients
in the PPS who achieved CC of CINV during the PEEP
was 193 (65%) in the oral granisetron group and 171 (60%)
in the GTDS group (Table 2). This equates to an estimated
difference in percentage CC between the groups of 5%
(95% CI, −13–3, Table 2).
Secondary and exploratory efficacy analyses
Examination of CC in predefined subgroups of the PPS,
based on known CINV risk factors, showed no significant
differences between the GTDS and oral granisetron in any
subgroup (Fig. 2). This indicates that the results of the
primary efficacy analysis are consistent across these
predefined subgroups. Additionally, analysis of CC in the
FAS gave similar results to those obtained in the PPS
(Table 2). The results of these exploratory analyses,
therefore, support the conclusion of non-inferiority of the
GTDS relative to oral granisetron.
The percentage of patients in the PPS who achieved
C Ra n dT Cd u r i n gt h eP E E Pi ss h o w ni nT a b l e2.N o
significant differences were observed in the percentages of
patients achieving CR and TC in the two treatment groups.
For those patients who did not achieve CC (113 and 105
treatment failures in the GTDS and oral groups, respec-
tively), the time to CC failure was similar for the two
groups (online resource, section 2). In patients receiving
3- and 5-day chemotherapy regimens, CC and CR were
similar between the GTDS and oral granisetron treatment
groups on all days of therapy (online resource, section 2,
Figure S2).
Patients’ global satisfaction with antiemetic therapy was
high with both treatments. The mean (±standard deviation)
VAS score for patients in the FAS was 8.19 cm (±2.21) for
GTDS-treated patients and 8.24 cm (±2.13) for oral
granisetron patients, p=0.887. There was no significant
difference between the two groups.
Patch adhesion
The adhesive properties of the active and placebo patches
were assessed in the FAS. Of 308 patients receiving the
GTDS, 198 (64%) had ≥90% adhesion and 277 (90%) had
≥75% adhesion. Two patients (1%) had a completely
detached patch. Of the 313 patients who received a placebo
patch, 244 (78%) had ≥90% adhesion and 299 (96%) had
≥75% adhesion. Three patients (1%) had a completely
detached patch.
Table 1 Patient baseline characteristics and therapy history (FAS)
GTDS (N=308) Oral granisetron
(N=313)
Age
Mean±SD (years) 54±13 55±14
≤40 years 15 15
>40 years 85 85
Physical characteristics
Weight, mean±SD (kg) 67±16 68±16
Height, mean±SD (cm) 164±10 164±11
BMI, mean±SD (kg/m
2) 25±5 25±67
Gender
a
Male 48 49
Female 52 51
Ethnic origin
White 76 80
Asian 14 10
Hispanic/Latino 9 10
Smoking status
Smoker 20 16
Ex-smoker 28 25
Never smoked 53 59
Current alcohol consumption
None 69 72
Monthly 20 18
Weekly 7 9
Daily 3 2
ECOG performance status
04 0 3 8
15 4 5 6
26 6
Metastatic disease
Yes 44 41
History of radiotherapy
Yes 20 21
Chemotherapy regimen
a
Cisplatin 71 72
Non-cisplatin + corticosteroids 20 19
Non-cisplatin – corticosteroids 8 9
Duration of chemotherapy
a
≤3 days 68 68
4/5 days 32 32
Chemotherapy naivety
a
Naïve 72 70
Non-naïve 28 30
Unless otherwise stated, data show percentage of patients
SD standard deviation
aGender, planned chemotherapy regimen and chemotherapy naivety were
used as stratification variables for randomization. Stratification of chemother-
apy regimens dividedregimens intocisplatin andnon-cisplatin chemotherapy.
Non-cisplatin regimens were further divided based on whether corticosteroids
were pre-planned for inclusion as antiemetics. The use of corticosteroids
concomitantly with cisplatin was not included in the stratification, but was
well balanced between treatment groups (data not shown)
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A total of 637 patients were included in the SS, of whom
254 experienced adverse events (GTDS, 128/316; oral
granisetron, 126/321). The majority of treatment-emergent
adverse events (TEAEs) were of mild or moderate severity,
and the incidence of TEAEs was comparable between the
GTDS (41%) and oral granisetron (39%) groups. The
majority of TEAEs were considered unrelated to the study
drugs. Study drug-related TEAEs that occurred throughout
the study are summarized in Table 3. The most common
study drug-related TEAE in both treatment groups was
constipation, which was reported more frequently by
patients receiving the GTDS than oral granisetron (7%
and 3%, respectively). In contrast, headache was reported
more frequently by patients receiving oral granisetron than
the GTDS (2.5% and 0.3%, respectively).
Local skin tolerability of the patch was good. Application
site pruritus was reported in two cases (both in the GTDS
group),ofwhichonlyonewasdeemedtobestudydrugrelated.
Serious TEAEs were reported by a total of 47 patients,
of which five were considered study drug related (oral
granisetron group: QTc prolongation, three and toxic
megacolon, one; GTDS group: constipation, one). There
were 15 deaths in the study population (seven GTDS and
eight oral granisetron patients), but only one (toxic mega-
colon,oralgranisetrongroup)wasregardedasrelatedtostudy
treatment. Seven patients in each group withdrew from the
study due to adverse events.
The ECGs of all patients were subjected to blinded
expert review. In 468 patients for whom full ECG data were
available, no clinically significant ECG morphology changes
were observed for either treatment, and no cases of QTc
prolongation were identified in the GTDS group.
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Chemotherapy
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Overall
emetogenicity
Female
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3
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4–5
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Moderate
cisplatin
+ CS
Non-
cisplatin
+ no CS
Non- Cisplatin High
Regimen
Non- Naïve
Fig. 2 Complete control of CINV in predefined subgroups of the PPS. CS corticosteroids
GTDS Oral granisetron Difference (%) 95% CI
n/N % n/N %
Per protocol set
Complete control 171/284 60 193/298 65 −4.9 −12.9–3.1
Complete response 176/284 62 203/298 68 −6.6 −14.4–1.3
Total control 158/284 56 177/298 59 −3.8 −11.8–4.3
Full analysis set
Complete control 185/308 60 205/313 65 −5.8 −13.5–2.0
Table 2 Complete control,
complete response and total
control of CINV in the PPS
and FAS
n number of patients achieving
response, N total number of
patients in the treatment group
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The current randomized trial represents the first direct
comparison of the efficacy of a transdermal 5-HT3 RA with
the oral dose form. The results of the primary efficacy
assessments indicated that the GTDS was non-inferior to
oral granisetron in the control of CINV in patients receiving
multi-day chemotherapy. Similar results were obtained in
exploratory analyses of the primary efficacy variable and in
secondary efficacy endpoints.
Based on the prespecified non-inferiority margin of 15%,
the results of this study indicate that the GTDS was non-
inferior to oral granisetron. A non-inferiority study design
was appropriate in this case, as both treatment arms used
the same active drug, and the GTDS was designed to give
equivalent systemic exposure to the established comparator.
The exploratory subgroup analyses and secondary
endpoints further support the conclusion of non-inferiority.
Importantly, efficacy was maintained when all grades of
nausea were included in the analysis, for both MEC and
HEC, and in patients with known CINV risk factors (online
resource, section 3). In addition, the GTDS maintained
CINV control from day to day, and was not inferior to oral
granisetron on any day of the PEEP (online resource,
Figure S2). The rates of CINV control observed on
individual days were similar to previously reported data
with granisetron (Kytril® Product Information 2005).
The addition of corticosteroids to 5-HT3 RA antiemetic
therapy improves emetic control, and is supported by
current guidelines [9]. The use of corticosteroids was
allowed in this study but not standardized, reflecting the
community standard of care across the countries included in
the study; however, steroid use was balanced between
treatment groups.
The adverse event profile of the GTDS observed in this
study indicates that it was well tolerated in cancer patients,
with adverse events reflective of those previously observed
for granisetron (Table 3). Skin tolerability of the patch
was good, as application site reactions were reported only
once by GTDS patients and did not cause any patients to
withdraw. Interestingly, the incidence of headache was
lower in the GTDS group than the oral granisetron group.
Constipation was reported more frequently in the GTDS
group than the oral granisetron group; however, all GTDS-
treated patients received granisetron for all 7 days of the
patch application period, whereas patients received oral
granisetron for 3–5 days, depending on the duration of
chemotherapy. Constipation was reported less frequently
than has been previously observed with intravenous 5-HT3
RAs [4, 13, 19].
The results show that the GTDS offers an effective well-
tolerated treatment option for CINV. Transdermal delivery
of granisetron carries an important advantage over repeated
oral dosing in terms of patient convenience, compliance,
GTDS Oral granisetron
(N=316) (N=321)
n % n %
Gastrointestinal disorders 22 7 12 3.7
Constipation 21 6.6 10 3.1
Abdominal pain 0 0 1 0.3
Irritable bowel syndrome 0 0 1 0.3
Megacolon 0 0 1 0.3
Nausea 1 0.3 0 0
General disorders and administrative site conditions 1 0.3 0 0
Application site pruritus 1 0.3 0 0
Metabolism and nutrition disorders 2 0.6 1 0.3
Anorexia 1 0.3 1 0.3
Decreased appetite 1 0.3 0 0
Nervous system disorders 1 0.3 8 2.5
Headache 1 0.3 8 2.5
Vascular disorders 1 0.3 0 0
Flushing 1 0.3 0 0
Investigations 1 0.3 3 0.9
ECG QT corrected interval prolonged 0 0 3 0.9
Weight decreased 1 0.3 0 0
Table 3 Study drug-related
treatment-emergent adverse
events in the GTDS and oral
granisetron groups (SS)
n number of patients with
adverse event, N total number of
patients in the treatment group
Support Care Cancer (2011) 19:1609–1617 1615and reduced pill burden. This may be especially valuable in
patients for whom swallowing is difficult or absorption of
oral medications is uncertain, such as patients with previous
head, neck, or gastrointestinal surgery or radiotherapy, or
comorbid conditions such as xerostomia [8]. Transdermal
granisetron provides additional choice for patients receiving
oral chemotherapy, for whom the absence of concurrent
intravenous therapies makes intravenous granisetron a less
attractive alternative. The convenience of the GTDS is
supported by its good adhesive properties, as demonstrated
in this study. Improving patient convenience may also act to
improve compliance with antiemetic therapy, with potential
benefits to quality of life, overall treatment satisfaction, and
compliance with future anticancer treatments [20].
Further investigation is needed to determine how the
pharmacokinetics of the 5-HT3 RAs affect their pharmaco-
dynamics; for example, it is unclear how the single-peak,
sustained pharmacokinetics of the GTDS might impact on
its efficacy compared to the reduced peak–tail fluctuations
observed with long-acting palonosetron [11, 13]. Such
investigations could also include addition of oral or
intravenous granisetron to the first day of GTDS therapy,
so as to achieve therapeutic levels of granisetron more
rapidly. Furthermore, it would be of interest to examine the
effects of combining the GTDS with NK-1 RAs, such as
aprepitant. NK-1 RAs were not included in this study, as
these agents were not available in some participating centers
at the time of study commencement. Given the previously
demonstrated efficacy of NK-1 RAs against delayed CINV
when added to 5-HT3 RA therapy [9], it would seem
reasonable to postulate that their addition to GTDS therapy
may improve control of CINV, particularly on the latter days
of chemotherapy. The addition of NK-1 RAs to GTDS
therapy wouldbeexpectedtobewelltolerated,as5-HT3 RAs
and NK-1 RAs are commonly used in combination.
The results of this randomized phase III study suggest
that the GTDS could provide a valuable new option for the
control of CINV in patients receiving multi-day chemo-
therapy regimens. Since 5-HT3 RAs, including granisetron,
are also used outside of CINV [21], the clinical application
of the GTDS may eventually be broadened.
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